MRTX - Mirati +22% after MRTX849 data shows tumor shrinkage October, 28 2019 05:34 PM Mirati Therapeutics Inc. Mirati Therapeutics (NASDAQ:MRTX) is up 22.2% after hours following results from its Phase 1/2 trial of MRTX849.More news on: Mirati Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...